What is the best course of treatment (COC) for perimenopausal symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For perimenopausal symptoms, the best combined oral contraceptive (COC) option is typically a low-dose formulation containing 20-35 mcg of ethinyl estradiol combined with a newer generation progestin such as norgestimate, desogestrel, or drospirenone. Specific products like Yaz/Yasmin (containing drospirenone), Ortho-Cyclen/Sprintec (containing norgestimate), or Desogen/Marvelon (containing desogestrel) are good choices. These should be taken daily for 21 days followed by 7 days of placebo pills, or continuously if breakthrough bleeding is not problematic. These COCs effectively manage irregular bleeding, hot flashes, mood swings, and sleep disturbances while providing contraception. They work by stabilizing hormone levels, suppressing ovulation, and providing exogenous estrogen to compensate for declining natural levels. Women should use these until approximately age 51-52 or until menopause is confirmed, then transition to hormone replacement therapy if symptoms persist. COCs are contraindicated in women with history of blood clots, uncontrolled hypertension, certain migraines, liver disease, or smokers over 35, so medical screening is essential before starting 1.

Some key points to consider:

  • The use of COCs for perimenopausal symptoms is supported by evidence from studies such as the Women's Health Initiative (WHI) 1.
  • The choice of COC should be individualized based on the woman's medical history, risk factors, and preferences 1.
  • Alternative options for managing perimenopausal symptoms, such as non-hormonal medications and lifestyle modifications, may also be considered 1.

It's essential to weigh the benefits and risks of COCs and other treatment options for perimenopausal symptoms, considering the individual woman's needs and health status 1.

From the Research

Best Contraceptive Options for Perimenopausal Symptoms

  • Combined hormonal contraception (CHC) is a suitable option for perimenopausal women, as it can relieve symptoms such as menstrual irregularities, hot flashes, and mood disorders 2, 3, 4.
  • Progestin-only methods can also be used, either alone or in combination with estrogen replacement therapy, to address both contraceptive needs and perimenopausal symptoms 2.
  • Nonhormonal options are available for women who wish to avoid hormonal methods 2.
  • The use of combined oral contraceptives (COCs) in perimenopausal women can help control menstrual irregularity, heavy menstrual bleeding, and vasomotor symptoms, while also reducing the risk of ovarian cancer, endometrial cancer, and colorectal cancer 5, 4.
  • A levonorgestrel intrauterine device with supplemental low-dose menopausal estrogen may be a suitable option for managing disruptive perimenopausal symptoms and long-term outcomes 6.

Considerations for Contraceptive Choice

  • Patient preference, medical co-morbidities, and perimenopausal symptoms should be taken into account when selecting a contraceptive method 2, 6.
  • Clinicians and pharmacists should address specific patient risk factors, symptom profiles, long-term risks and benefits, and patient preferences when choosing a contraceptive for perimenopausal women 6.
  • There is no evidence that taking COCs presents an increased risk of cardiovascular events or breast cancer for middle-aged women, and age itself is not a contraindication for COC use 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Perimenopausal contraception.

Current opinion in obstetrics & gynecology, 2020

Research

Oral contraceptive use in perimenopause.

American journal of obstetrics and gynecology, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.